Advancing the Prevention of Postherpetic Neuralgia: Methodological and Clinical Considerations for the TPI Study Protocol [Letter]

Multicenter, Blinded Endpoint, Open-Label Controlled Trial". 1 The authors address a critical clinical challenge: the prevention of postherpetic neuralgia (PHN), a debilitating condition that often remains refractory to conventional pharmacological therapies.By investigating a simple, low-cost, and potentially high-impact intervention-Tender Point Infiltration (TPI) with lidocaine and betamethasone-this multicenter RCT provides a promising framework for early intervention in zoster-associated pain (ZAP).However, from the perspective of clinical pain management and trial methodology, several points merit further discussion to enhance the robustness and interpretability of the forthcoming results. Defining Postherpetic Neuralgia: The Threshold of Clinical SignificanceIn this protocol, the primary outcome is defined as the presence of PHN at 12 months, identified as any persistent pain with a Visual Analogue Scale (VAS) score >0. 1 While this "zero-tolerance" approach toward pain is scientifically rigorous, its clinical relevance warrants scrutiny.In many landmark HZ trials, PHN is defined by a more clinically significant threshold, such as VAS 3 or the continued need for analgesics, to distinguish between mild sensory disturbances and functionally impairing chronic pain. 2 Using VAS >0 may lead to an overestimation of PHN incidence by including patients with negligible discomfort that does not affect quality of life.We suggest that the authors consider a sensitivity analysis using a higher pain threshold (eg, VAS 3) to ensure that the observed "preventive effect" of TPI translates into a meaningful reduction in the clinical burden of PHN. The Placebo Effect and Expectancy Bias in Open-Label Injection TrialsThe study adopts an open-label design, comparing standard treatment alone with standard treatment plus TPI.As the authors correctly acknowledge, blinding the TPI procedure is challenging.However, physical interventions involving needles and local anesthesia are known to induce substantial placebo and expectancy effects. 3,4In an open-label setting, patients in the TPI group might report lower VAS scores and higher satisfaction due to the perceived "intensified" care rather than the pharmacological action of the infiltrates.While the use of blinded endpoint assessment (PROBE design) mitigates detection bias, it cannot fully eliminate the performance bias inherent in the patient's self-reported pain scores.Future studies might benefit from a sham-injection control group (eg, superficial skin pricking or saline injection) to isolate the specific therapeutic effect of TPI from the non-specific effects of the procedure itself.